» Articles » PMID: 20206418

3D QSAR Pharmacophore Based Virtual Screening and Molecular Docking for Identification of Potential HSP90 Inhibitors

Overview
Journal Eur J Med Chem
Specialty Chemistry
Date 2010 Mar 9
PMID 20206418
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Chemical features based 3D pharmacophore models were developed for HSP90 based on the known inhibitors using Discovery Studio V2.1. An optimal pharmacophore model was brought forth and validated using a decoy set, external test set and Fischer's randomization method. The best five features pharmacophore model, Hypo1, includes two hydrogen bond acceptors, three hydrophobic features, which has the highest correlation coefficient (0.93), cost difference (73.88), low RMS (1.24), as well as it shows a high goodness of fit and enrichment factor. Hypo1 was used as a 3D query for virtual screening to retrieve potential inhibitors from Maybridge and Scaffold databases. The hit compounds were subsequently subjected to molecular docking studies and finally, 36 compounds were obtained based on consensus scoring function.

Citing Articles

Study of interaction energies between residues of the active site of Hsp90 and geldanamycin analogues using quantum mechanics/molecular mechanics methods.

Vivas-Reyes R, Morales-Bayuelo A, Gueto C, Drosos J, Marquez Lazaro J, Baldiris R F1000Res. 2023; 8:2040.

PMID: 37767457 PMC: 10521063. DOI: 10.12688/f1000research.20844.2.


LSD1-Based Reversible Inhibitors Virtual Screening and Binding Mechanism Computational Study.

Yin Z, Liu S, Yang X, Chen M, Du J, Liu H Molecules. 2023; 28(14).

PMID: 37513188 PMC: 10383809. DOI: 10.3390/molecules28145315.


3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors.

Kumar V, Parate S, Danishuddin , Zeb A, Singh P, Lee G Front Cell Infect Microbiol. 2022; 12:909111.

PMID: 35846777 PMC: 9280624. DOI: 10.3389/fcimb.2022.909111.


Identification of Potent and Selective JAK1 Lead Compounds Through Ligand-Based Drug Design Approaches.

Babu S, Nagarajan S, Sathish S, Negi V, Sohn H, Madhavan T Front Pharmacol. 2022; 13:837369.

PMID: 35529449 PMC: 9068899. DOI: 10.3389/fphar.2022.837369.


Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation.

Kumbhar N, Nimal S, Barale S, Kamble S, Bavi R, Sonawane K Sci Rep. 2022; 12(1):1712.

PMID: 35110603 PMC: 8810932. DOI: 10.1038/s41598-022-05698-7.